Conquering RAS From Biology to Cancer Therapy
Auteur : Azmi Asfar
Conquering RAS: From Biology to Cancer Therapy provides introductory knowledge on how modern RAS biology is taking shape in light of newer technological development. Each chapter is written in a manner that emphasizes simplicity and readability for both new investigators and established researchers. While RAS biology has been intensively studied for more than three decades, we are yet to see any effective therapeutics that could interfere in the signaling cascade regulated by this master oncogene.
The book covers topics ranging from basic RAS biology, to translational biology and drug discovery applications. These topics will be appealing to basic researchers working in labs who seek deeper understanding of the modern concepts in RAS research. On the other side, the oncologist at the patient?s bedside will find the book useful as they routinely face the daunting task of treating patients that predominantly have a disease driven by oncogenic KRAS.
SECTION I: RAS CANCER BIOLOGY1. Ras and RASSF effector proteins / Jessica N. Mezzanotte and Geoffrey J. Clark2. Ras and the Hippo pathway in cancer / Eric O'Neill3. The Many Roles of RalGTPases in Ras-driven Cancer / David F. Kashatus4. The biology, prognostic relevance and targeted treatment of Ras pathway positive childhood acute lymphoblastic leukemia / Julie Anne Elizabeth Irving5. Oncogenic KRAS and the Inflammatory Microenvironment in Pancreatic Cancer / Hui-Hua Chang, Andrea Schmidt and Guido Eibl6. Activation of Ras by Post-Translational Modifications / Shengyan Xiang, Wenlong Bai, Gerold Bepler and Xiaohong Zhang7. Cross talk between Snail and mutant K-ras contributes to pancreatic cancer progression / Christina R. Chow, Kazumi Ebine, Holly Z. Hattaway, Krishan Kumar and Hidayatullah G. Munshi
SECTION II: NOVEL THERAPEUTIC APPROACHES TARGETING RAS AND RELATED PATHWAYS8. Search for Inhibitors of Ras-Driven Cancers / Adam B. Keeton and Gary A. Piazza9. GTP-competitive inhibitors of RAS family members / John C. Hunter and Kenneth D. Westover10. Next generation strategies to target RAF / Darrin D. Stuart11. Targeting metabolic vulnerabilities in Ras-mutant cells / Aparna D Rao and Grant A McArthur12. Blocking SIAH proteolysis, an important K-RAS vulnerability, to control and eradicate K-RAS-driven metastatic cancer / Robert Van Sciver, Monicah M. Njogu, Andrew J. Isbell, Justin J. Odanga, Minglei Bian, Elizaveta Svyatova, Lauren L. Siewertsz van Reesema, Vasilena Zheleva, Jamie L. Eisner, Jamie K. Bruflat, Rebecca L. Schmidt, Angela M. Tang-Tan, and Amy H. Tang13. Extracellular signal-regulated kinases (ERK1 and ERK2) Inhibitors / Ahmad Samatar14. Targeting Rho, Rac, CDC42 GTPase effector p21 activated kinases in cancer / Asfar Sohail Azmi; Philip A. Philip
Dr. Azmi’s lab has made significant pre-clinical discoveries in advanced animal tumor models that helped the clinical development of new cancer drugs. Dr. Azmi has considerable experience in the area of early phase clinical research. Several agents developed by his team have gone into Phase II clinical studies. He has published more than 100 cancer research articles and has edited three additional books, among which there are the Elsevier publications Molecular Diagnostics and Treatment of Pancreatic Cancer as well as Conquering Ras. He is the recipient of numerous young investigator awards from premier scientific bodies. The National Institute of Health and pharmaceutical industry have continuously funded his lab.
- Brings together wide ranging topics in RAS basic and translational biology for the scientific and clinical communities
- Showcases recent advancements in RAS research under one comprehensive volume
- Includes video clips, color illustrations, and important website links to facilitate a clear understanding of RAS in cancer research
Date de parution : 09-2016
Ouvrage de 294 p.
19x23.3 cm
Thèmes de Conquering RAS :
Mots-clés :
Acetylation; Apoptosis; Autophagy; BRAF; Cancer stem cells; Cancer; Childhood acute lymphoblastic leukemia; Covalent inhibitor; CRAF; DNA repair; Drug resistance; EGFR; EMT; Epigenetic inactivation; Epithelial�mesenchymal transition; ERK; Exocyst; Farnesylation; Fibrosis; G12C; Genetic screen and genetic epistasis; Geranylgeranylation; Glutamine; Glycolysis; GPCR; Hippo; Inflammation; Inhibitors; Irreversible inhibitor; Kinact; Kinase inhibitor; K-RAS signaling pathway; KRAS; K-ras; Macropinocytosis; MAPK; MEK; Melanoma; Metabolic re-programming; Modification; Mutant BRAF; Mutant RAS; Mutation; Negative feedback; NORE1A; Obesity; Oncogene; Oncogenic KRAS; Oxidative phosphorylation; P21 activated kinases; Pak 4 allosteric modulators; PAK4; PAKs; Palmitoylation; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Phosphorylation; Prenylation; Prognosis; RAF dimerization; RalA; RalB; RalBP1; Ras GTPase; Ras pathway; Ras; RAS; RAS-Driven tumor invasion and cancer metastasis; RASSF1A; Relapse; Resistance; Senescence; Signal transduction; SINA and SIAH family of RING domain E3 ligases; Small molecule inhibitors; Snail; S-nitrosylation; Stem cells; Targeted therapy; TBK1; Tumor suppressor; Tumor; Ubiquitination; Ubiquitin-mediated proteolysis
